A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
Status:
Completed
Trial end date:
2019-07-26
Target enrollment:
Participant gender:
Summary
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm
study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with
placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving
medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following
additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier
(LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The
total duration of this study for each participant is approximately 70 weeks including
screening, run-in, treatment, and follow-up.